CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CX-904’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CX-904 overview
CX-904 is under development for the treatment of solid tumors including colorectal cancer, metastatic pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma (HNSCC), gastric cancer and esophageal cancer. The drug candidate is a bispecific T cell engager (BiTE) that acts by targeting both cluster of differentiation (CD3) and epidermal growth factor receptor (EGFR). It is developed based on probody platform which is designed to localize antibody binding to a diseased tissue. It is a prodrug.
CytomX Therapeutics overview
CytomX Therapeutics (Cytomx) is a clinical-stage biopharmaceutical company. It develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s product pipeline include CX-2029, CX-904 and BMS-986288. Its pipeline carries out SqNSCLC, esophageal/GEJ and solid tumors. Cytomx provides probody therapeutics for the treatment of cancer. The company also carries out various phases of clinical trails. Cytomx is headquartered in South San Francisco, California, the US.
For a complete picture of CX-904’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
